Health Condition 1: B360- Pityriasis versicolor
Conditions
Interventions
Intervention1: Luliconazole: Group B-Luliconazole 1% cream twice daily for 2 weeks
Control Intervention1: Ketoconazole: Group B-Ketoconazole 2% cream twice daily for 2 weeks
Control Intervention2: Ket
Sponsors
Pt BD Sharma PGIMS Rohtak
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either gender over 18 years of age 2. Patients having lesions on face, neck and thorax 3. Patients with a clinical diagnosis of tinea versicolor, confirmed by microscopic KOH test
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating females 2. Patients with: i. Contact dermatitis, Atopic dermatitis or other skin diseases ii. Other tinea infections iii. Hypersensitivity to study drugs iv. Therapy on other antifungal within a month v. Serious concomitant illness vi. Extensive tinea versicolor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Four point scale for assessment of erythema, scaling, pruritis & hypo or hyperpigmentation 2. Microscopic Examination (KOH mount) Timepoint: Safety assessment will be carried out in the two study groups at 1 2 & 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Visual Analogue scale (VAS) for assessment of pruritis & erythema 2. Global clinical assessment scale 3. Number of patients requiring escape treatment Timepoint: Safety assessment will be carried out in the two study groups at 1 2 & 4 weeks | — |
Countries
India
Contacts
Public ContactDr Gishnu Ravi Ram K
Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak
Outcome results
None listed